Taribavirin
Antiviral drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Taribavirin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Not to be confused with tribavirin, which is ribavirin.
Taribavirin (rINN; also known as viramidine, codenamed ICN 3142) is an antiviral drug in Phase III human trials, but not yet approved for pharmaceutical use. It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active. These include hepatitis C and perhaps also hepatitis B and yellow fever.
Quick Facts Clinical data, Other names ...
Clinical data | |
---|---|
Other names | 1-(β-D-Ribofuranosyl)- 1,2,4-triazole-3-carboximide |
Pregnancy category |
|
Routes of administration | Oral capsules) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 9% |
Metabolism | Metabolized to 5'phosphates, de-riboside, and deriboside carboxylic acid |
Elimination half-life | 12 days - Multiple Dose; 120-170 hours - Single Dose |
Excretion | 10% fecal, remainder in urine (30% unchanged, remainder metabolites) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H13N5O4 |
Molar mass | 243.223 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close